Literature DB >> 27141339

PD-1 expression on dendritic cells suppresses CD8+ T cell function and antitumor immunity.

Tong Seng Lim1, Valerie Chew2, Je Lin Sieow3, Siting Goh3, Joe Poh-Sheng Yeong4, Ai Ling Soon3, Paola Ricciardi-Castagnoli5.   

Abstract

Programmed death one (PD-1) is a well-established co-inhibitory regulator that suppresses proliferation and cytokine production of T cells. Despite remarkable progress in delineating the functional roles of PD-1 on T lymphocytes, little is known about the regulatory role of PD-1 expressed on myeloid cells such as dendritic cells (DCs). Here, we show that CD8+ T cells can be more potently activated to secrete IL-2 and IFNγ by PD-1-deficient DCs compared to wild-type DCs. Adoptive transfer of PD-1-deficient DCs demonstrated their superior capabilities in inducing antigen-specific CD8+ T cell proliferation in vivo. In addition, we provide first evidence demonstrating the existence of peripheral blood DCs and CD11c+ tumor-infiltrating myeloid cells that co-express PD-1 in patients with hepatocellular carcinoma (HCC). The existence of PD-1-expressing HCC-infiltrating DCs (HIDCs) was further supported in a mouse model of HCC. Intratumoral transfer of PD-1-deficient DCs rendered recipient mice resistant to the growth of HCC by promoting tumor-infiltrating CD8+ effector T cells to secrete perforin and granzyme B. This novel finding provides a deeper understanding of the role of PD-1 in immune regulation and has significant implications for cancer immunotherapies targeting PD-1.

Entities:  

Keywords:  Antitumor immunity; Programmed death one (PD-1); cancer immunotherapy; dendritic cell; hepatocellular carcinoma; liver cancer

Year:  2015        PMID: 27141339      PMCID: PMC4839350          DOI: 10.1080/2162402X.2015.1085146

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN: 2162-4011            Impact factor:   8.110


  41 in total

1.  Tumor immunotherapy directed at PD-1.

Authors:  Antoni Ribas
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

Review 2.  Clinical blockade of PD1 and LAG3--potential mechanisms of action.

Authors:  Linh T Nguyen; Pamela S Ohashi
Journal:  Nat Rev Immunol       Date:  2015-01       Impact factor: 53.106

3.  Molecular pathogenesis of hepatocellular carcinoma in hepatitis B virus transgenic mice.

Authors:  F V Chisari; K Klopchin; T Moriyama; C Pasquinelli; H A Dunsford; S Sell; C A Pinkert; R L Brinster; R D Palmiter
Journal:  Cell       Date:  1989-12-22       Impact factor: 41.582

4.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Authors:  Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Richard D Carvajal; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Leora Horn; Charles G Drake; Drew M Pardoll; Lieping Chen; William H Sharfman; Robert A Anders; Janis M Taube; Tracee L McMiller; Haiying Xu; Alan J Korman; Maria Jure-Kunkel; Shruti Agrawal; Daniel McDonald; Georgia D Kollia; Ashok Gupta; Jon M Wigginton; Mario Sznol
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

Review 5.  Advances in targeting cell surface signalling molecules for immune modulation.

Authors:  Sheng Yao; Yuwen Zhu; Lieping Chen
Journal:  Nat Rev Drug Discov       Date:  2013-02       Impact factor: 84.694

6.  Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2.

Authors:  Tadashi Yokosuka; Masako Takamatsu; Wakana Kobayashi-Imanishi; Akiko Hashimoto-Tane; Miyuki Azuma; Takashi Saito
Journal:  J Exp Med       Date:  2012-05-28       Impact factor: 14.307

7.  Hydronephrosis associated with antiurothelial and antinuclear autoantibodies in BALB/c-Fcgr2b-/-Pdcd1-/- mice.

Authors:  Taku Okazaki; Yumi Otaka; Jian Wang; Hiroshi Hiai; Toshiyuki Takai; Jeffrey V Ravetch; Tasuku Honjo
Journal:  J Exp Med       Date:  2005-12-13       Impact factor: 14.307

8.  Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death.

Authors:  Y Ishida; Y Agata; K Shibahara; T Honjo
Journal:  EMBO J       Date:  1992-11       Impact factor: 11.598

9.  A contribution of mouse dendritic cell-derived IL-2 for NK cell activation.

Authors:  Francesca Granucci; Ivan Zanoni; Norman Pavelka; Serani L H Van Dommelen; Christopher E Andoniou; Filippo Belardelli; Mariapia A Degli Esposti; Paola Ricciardi-Castagnoli
Journal:  J Exp Med       Date:  2004-08-02       Impact factor: 14.307

Review 10.  Regulation of immune reactivity by intercellular transfer.

Authors:  Maxime Dhainaut; Muriel Moser
Journal:  Front Immunol       Date:  2014-03-28       Impact factor: 7.561

View more
  62 in total

Review 1.  PD-1 immunobiology in systemic lupus erythematosus.

Authors:  Colleen S Curran; Sarthak Gupta; Ignacio Sanz; Elad Sharon
Journal:  J Autoimmun       Date:  2018-11-03       Impact factor: 7.094

2.  Engineering of a novel subnanomolar affinity fibronectin III domain binder targeting human programmed death-ligand 1.

Authors:  Sindhuja Ramakrishnan; Arutselvan Natarajan; Carmel T Chan; Paramjyot Singh Panesar; Sanjiv S Gambhir
Journal:  Protein Eng Des Sel       Date:  2019-12-31       Impact factor: 1.650

3.  A unique variant of lymphocytic choriomeningitis virus that induces pheromone binding protein MUP: Critical role for CTL.

Authors:  Brian C Ware; Brian M Sullivan; Stephanie LaVergne; Brett S Marro; Toru Egashira; Kevin P Campbell; John Elder; Michael B A Oldstone
Journal:  Proc Natl Acad Sci U S A       Date:  2019-08-19       Impact factor: 11.205

Review 4.  Immune checkpoint-based therapy in myeloid malignancies: a promise yet to be fulfilled.

Authors:  Jan Philipp Bewersdorf; Maximilian Stahl; Amer M Zeidan
Journal:  Expert Rev Anticancer Ther       Date:  2019-03-19       Impact factor: 4.512

Review 5.  Trial watch: Immune checkpoint blockers for cancer therapy.

Authors:  Claire Vanpouille-Box; Claire Lhuillier; Lucillia Bezu; Fernando Aranda; Takahiro Yamazaki; Oliver Kepp; Jitka Fucikova; Radek Spisek; Sandra Demaria; Silvia C Formenti; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2017-08-31       Impact factor: 8.110

Review 6.  Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications.

Authors:  Mariona Cabo; Rienk Offringa; Laurence Zitvogel; Guido Kroemer; Aura Muntasell; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2017-08-30       Impact factor: 8.110

Review 7.  Trial watch: Immunogenic cell death induction by anticancer chemotherapeutics.

Authors:  Abhishek D Garg; Sanket More; Nicole Rufo; Odeta Mece; Maria Livia Sassano; Patrizia Agostinis; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2017-10-04       Impact factor: 8.110

Review 8.  Tumor microenvironmental influences on dendritic cell and T cell function: A focus on clinically relevant immunologic and metabolic checkpoints.

Authors:  Kristian M Hargadon
Journal:  Clin Transl Med       Date:  2020-01

9.  Endometriosis stromal cells induce bone marrow mesenchymal stem cell differentiation and PD-1 expression through paracrine signaling.

Authors:  Peng Chen; Ramanaiah Mamillapalli; Shutaro Habata; Hugh S Taylor
Journal:  Mol Cell Biochem       Date:  2021-01-11       Impact factor: 3.396

10.  Checkpoint Blockade Immunotherapy Induces Dynamic Changes in PD-1-CD8+ Tumor-Infiltrating T Cells.

Authors:  Sema Kurtulus; Asaf Madi; Giulia Escobar; Max Klapholz; Jackson Nyman; Elena Christian; Mathias Pawlak; Danielle Dionne; Junrong Xia; Orit Rozenblatt-Rosen; Vijay K Kuchroo; Aviv Regev; Ana C Anderson
Journal:  Immunity       Date:  2019-01-08       Impact factor: 31.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.